Global Monoclonal Antibody Therapeutics Market Growth, Share, Size, Trends and Forecast (2022 - 2028)

This report extensively covers different segments of Global Monoclonal Antibody Therapeutics Market and provides an in depth analysis (including revenue analysis for both historic and forecast periods) for all the market segments. In this report, the analysis for every market segment is substantiated with relevant data points and, insights that are generated from analysis of these data points (data trends and patterns).

Global Monoclonal Antibody Therapeutics Market Analysis

In this report, the Global Monoclonal Antibody Therapeutics Market has been segmented by Application Type, Source , End User and Geography. The global monoclonal antibody market is segmented based on source, production, indication, end user, and region. Based on source, it is classified into murine, chimeric, humanized, and human. Based on production, it is divided into in vivo and in vitro. Muromonab cd3 a murine mab was the first fda approved therapeutic mab for the prevention of kidney transplant rejection. Since its approval in 1986, there has been a decline in further application and approvals until the late 1990s when the first chimeric mab, rituximab was approved for the treatment of lowgrade. Monoclonal Antibodies: A Review With the advent of fully human MAbs, the efficacy and safety have improved in the treatment of various cardiovascular, cancer, respiratory, hematology, autoimmune diseases and infections. The introduction of biosimilars will increase the affordability and utilization of MAbs in the treatment. Production of human or humanized antibodies in mice Mice are widely available laboratory animals that can easily be used for the production of antibodies against a broad range of antigens, using well-defined immunization protocols. Such an approach allows optimal in vivo affinity maturation of the humoral response. The successful development of antibody drugs from phage display. Fully human therapeutic antibodies in current clinical use were discovered from either phage display or transgenic mice approaches . Phage display has the advantage of allowing researchers to tailor critical characteristics of successful antibody drugs (e.g., affinity, specificity. This review presents an overview of the methods available for the de novo generation of human antibodies, for engineering antibodies with increased antigen affinity, and for the production of antibody fragments. Select applications of recombinant antibodies are also presented.

Global Monoclonal Antibody Therapeutics Market, Segmentation by Geography

In this report, the Global Monoclonal Antibody Therapeutics Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Find below the list of Countries covered in each of the aforementioned geographical regions:

North America - United States, Canada and Mexico

Latin America - Brazil, Argentina and Rest of Latin America

Europe - Germany, United Kingdom, France, Italy, Spain and Rest of Europe

Asia Pacific - Japan, China, India, Australia & New Zealand, South Korea, ASEAN (Association of South East Asian Nations) and Rest of Asia Pacific

Middle East & Africa - GCC Countries, Egypt, Israel, South Africa, Rest of Middle East & Africa

This report provides market size in USD Million and Year on Year (YOY) percentage growth analysis for the Monoclonal Antibody Therapeutics Market in all the Regions and Countries (specified above) for historic (2018 - 2021) and forecast (2022 - 2028) Periods with 2021 considered as the base year.

This report also provides an analysis of why the market size of Monoclonal Antibody Therapeutics in various regions and countries is increasing or decreasing with time along with the reasons for changes in the YOY growth with time.

This report provides an in depth analysis of various factors that impact the dynamics of Global Monoclonal Antibody Therapeutics Market. These factors include; Market Drivers, Restraints and Opportunities Analysis, Market Opportunity Mapping, PEST (Political, Economic, Social and Technological) Analysis and Porter's Five Forces Analysis.

Drivers, Restraints and Opportunity Analysis

Market Opportunity Map

This report provides market opportunity map for Monoclonal Antibody Therapeutics Market. The opportunity map (by market segments; Application Type, Source and End User) is calculated based on current year market estimates, CAGR and collective revenue over the forecast period. Since, CAGR has been estimated considering all the factors impacting the market; starting from the company's presence, buyer behaviour, to government interference or support. The opportunity map inherently considers all the aforementioned factors impacting the market. The bubble size reflects the estimated opportunity for a particular segment or region, therefore, bigger the bubble size, larger the opportunity.

PEST (Political, Economic, Social and Technological) Analysis

This report provides PEST analysis of Monoclonal Antibody Therapeutics Market. Various factors such as government interference in the market such as regulations (which include but are not limited to pricing and intellectual property policies) that might impact the market are analysed.

This report also provides an analysis of Economic factors affecting the market such as; purchasing power, which directly influences the market growth.

This report also provides an analysis of social factors such as social norms or cultural beliefs inhibiting or promoting the growth of the market

As part of PEST analysis, this report also provides analysis of the impact of Technological factors on growth or decline of a market.

Porter's Five Force Analysis

This report provides Porter's Five Forces analysis of Global Monoclonal Antibody Therapeutics Market, which include; Bargaining Power of Suppliers, Bargaining Power of Buyers, Threat of New Entrants, Threat of Substitutes and Competitive Rivalry.

Bargaining Power of Suppliers:

Various factors such as; Supplier Switching Costs Relative to Firm Switching Costs, Supplier Competition and Possibility of Forward Integration, Presence of Substitute Inputs, Strength of Distribution Channels, and Supplier Concentration to Firm Concentration Ratio would be analysed to estimate bargaining power of suppliers in the Global Monoclonal Antibody Therapeutics Market. Bargaining power of suppliers will be reported on a scale of 0-10 with 0 being the lowest value and 10 being the highest value.

Bargaining Power of Buyers:

Various factors such as; Buyer Concentration to Firm Concentration Ratio, Buyer Switching Costs, Availability of Existing Substitute Products, Buyer Price Sensitivity, and Degree of Dependency upon Existing Channels of Distribution would be analysed to estimate bargaining power of buyers in the Global Monoclonal Antibody Therapeutics Market. Bargaining power of buyers will be reported on a scale of 0-10 with 0 being the lowest value and 10 being the highest value.

Threat of Substitutes:

Various factors such as; Availability of Substitutes, Number of Available Substitutes, Price of Substitute Products, Buyer Switching Costs, and Buyer Propensity to Substitute would be analysed to estimate threat of substitutes in the Global Monoclonal Antibody Therapeutics Market. Threat of substitutes will be reported on a scale of 0-10 with 0 being the lowest value and 10 being the highest value.

Threat of New Entrants:

Various factors such as; Barriers to Entry, Economies of Scale, Product Differentiation, Customer Loyalty, Network Effect, and Access to Distribution Channels would be analysed to estimate threat of new entrants in the Global Monoclonal Antibody Therapeutics Market. Threat of new entrants will be reported on a scale of 0-10 with 0 being the lowest value and 10 being the highest value.

Competitive Rivalry:

Various factors such as; Firm concentration Ratio, Level of Advertising Expense, Sustainable Competitive Advantage through Innovation, Competitive Strategy and Degree of Transparency would be analysed to estimate competitive rivalry in the Global Monoclonal Antibody Therapeutics Market. Competitive rivalry will be reported on a scale of 0-10 with 0 being the lowest value and 10 being the highest value.

Key players in Global Monoclonal Antibody Therapeutics Market include, Pfizer Inc., Bayer AG, Sanofi, Merck & Co., Inc., GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd., Novartis AG and Holdings AbbVie Inc.

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis

This report also provides Heat map analysis of Products/Services Offered by different companies operating in this market.